Koen Breyne is an Assistant Professor of Neurology at Harvard Medical School (HMS) and Massachusetts General Hospital (MGH), with a background in Biochemistry and Biotechnology. He completed his Ph.D. in 2015 at Ghent University and pursued postdoctoral training at UChicago and MGH. Dr. Breyne has extensive expertise in molecular biology, extracellular vesicles, and immunology. His research is dedicated to advancing innovative diagnostics and therapies, with a focus on hereditary neurological disorders and brain cancer.

Pierre is a PhD student from the University of Geneva, where he completed his studies in pharmacy. In the BreyneLab, he investigates how adenosine-mediated immunosuppression shapes the glioblastoma microenvironment, focusing on its impact on dendritic cell function and CD8⁺ T cell activity. His project aims to develop therapeutic strategies that combine A2A receptor blockade with standard chemotherapy to restore dendritic cell–driven T cell priming and enhance anti-tumor cytotoxic responses. Through in vivo glioma models and ex vivo analyses of human tumor samples, Pierre’s work seeks to uncover how adenosine signaling impairs immune activation and to identify ways to reinvigorate local anti-tumor immunity.

Edwina Abou Haidar is a medical graduate from St. George’s University of London and holds a master’s degree in molecular biology from the Lebanese American University. Currently, as a postdoctoral research fellow at HMS/MGH, she is dedicated to advancing pre-clinical gene therapy in mouse models of Tuberous Sclerosis Types 1 and 2 and Neurofibromatosis Types 1 and 2. In the BreyneLab, Edwina is exploring the potential of EVs released by AAV-transduced cells to enhance therapeutic protein delivery in a TSC1 mouse model.

Tyler (Tianhe Xiao) targets brain cells in glioblastoma mouse models using non-invasive routes with adeno-associated virus (AAV) vectors, similar to those used in patient gene therapy. In the BreyneLab, he tracks AAV-labeled brain cells to assess their recruitment efficiency by glioblastoma. His goal is to develop novel interventions where glioblastoma-recruited cells act as reservoirs for delivering therapeutics directly to the tumor.

Kevin Leandro is a visiting PhD student at MGH/HMS from the Center for Neuroscience and Cell Biology at the University of Coimbra, Portugal. He is engineering extracellular vesicles as a platform to deliver CRISPR-Cas technologies in the context of neurodegenerative disorders. In the BreyneLab, Kevin aims to enhance the delivery of therapeutic cargo to the brain.

Mia Gurevich, a student at Brandeis University, MA, has a keen interest in gene therapy. In the Breyne Lab, she is testing prime editing therapies to treat the dGAG mutation found in neurological disease patients with DYT1 Dystonia.

Elie is an MD who graduated from Saint Joseph University of Beirut. As a postdoctoral researcher in the BreyneLab, Elie analyzes olfactory cell subsets and their interactions with glioblastoma cells. His findings uncover the mechanisms by which glioblastoma reprograms olfactory cells and the role these reprogrammed cells play in the progression and maintenance of the tumor.

Merel Korstanje is a visiting biomedical sciences student from Leiden University in the Netherlands. While at the BreyneLab, she focuses on addressing the challenges associated with the recombinant loading of extracellular vesicles. Her work aims to advance genome editing techniques to treat hereditary neurological diseases. Merel’s research involves developing methods to ensure the efficient delivery of therapeutic agents via extracellular vesicles, ultimately contributing to the potential treatment of DYT1 dystonia and similar disorders.